PROVECTUS BIOPHARMACEUTICALS, INC. — Revenue by Fiscal Year
9 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/1a0f9045-1753-40a0-b1a3-9eb72472d9ed/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $336.1k | 2025-01-01 – 2025-12-31 | evidence 0001493152-26-012726 |
| FY 2024 | $617.1k | 2024-01-01 – 2024-12-31 | evidence 0001641172-25-000993 |
| FY 2023 | $557.7k | 2023-01-01 – 2023-12-31 | evidence 0001493152-24-011699 |
| FY 2022 | $989.0k | 2022-01-01 – 2022-12-31 | evidence 0001493152-23-009563 |
| FY 2015 | $0 | 2015-01-01 – 2015-12-31 | evidence 0001193125-16-523701 |
| FY 2014 | $0 | 2014-01-01 – 2014-12-31 | evidence 0001193125-15-088039 |
| FY 2013 | $39.8k | 2002-01-18 – 2014-03-31 | evidence 0001193125-14-188810 |
| FY 2012 | $39.8k | 2002-01-18 – 2013-03-31 | evidence 0001193125-13-211517 |
| FY 2011 | $39.8k | 2002-01-16 – 2012-03-31 | evidence 0001193125-12-221968 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
PROVECTUS BIOPHARMACEUTICALS, INC. — all facts · Net Income · Operating Income